Immunovant, Inc. Form 10-Q Summary
Business context and reporting period
Immunovant is a clinical-stage biopharmaceutical company focused on autoimmune diseases. Its sole product candidate is batoclimab, an anti-FcRn monoclonal antibody intended to reduce pathogenic IgG antibodies. The filing covers the three and nine months ended December 31, 2021, within the fiscal year ending March 31, 2022. The financial statements are unaudited and prepared under U.S. GAAP.
Financial metrics
| Metric | Three months ended Dec. 31, 2021 | Three months ended Dec. 31, 2020 | Nine months ended Dec. 31, 2021 | Nine months ended Dec. 31, 2020 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $29.8 million | $21.1 million | $69.8 million | $50.0 million |
| General and administrative expense | $11.5 million | $10.5 million | $39.0 million | $29.2 million |
| Total operating expenses | $41.3 million | $31.6 million | $108.8 million | $79.2 million |
| Net loss | $41.4 million | $31.8 million | $109.6 million | $79.3 million |
| Net loss per share | $0.36 | $0.32 | $1.02 | $0.94 |
| Cash used in operating activities | Not separately provided | Not separately provided | $73.2 million | $60.8 million |
As of December 31, 2021, cash was $527.0 million, compared with $400.1 million at March 31, 2021. Total assets were $543.2 million, total liabilities were $38.0 million, and stockholders’ equity was $505.1 million. Accumulated deficit was $308.2 million. The filing reports no debt financing outstanding; operating lease liabilities were $2.8 million in total.
Financing activities provided $200.1 million during the first nine months of fiscal 2022, primarily from the issuance of 17.0 million common shares to Roivant Sciences Ltd. for $200.0 million. Investing activities used $0.1 million, primarily for property and equipment. Stock-based compensation was $22.4 million for the nine-month period, compared with $13.3 million in the prior-year period.
Material changes versus the prior comparable period
- Quarterly research and development expense increased $8.7 million, or approximately 41%, to $29.8 million. The increase was driven primarily by contract manufacturing, personnel, cross-indication clinical research and other unallocated costs, despite lower indication-specific trial activity during the clinical pause.
- Nine-month research and development expense increased $19.8 million, or approximately 40%, to $69.8 million, reflecting higher personnel, drug-substance manufacturing and clinical research spending.
- Quarterly general and administrative expense increased $1.0 million to $11.5 million. Nine-month general and administrative expense increased $9.8 million to $39.0 million, including $5.0 million of financial advisory fees related to potential transactions explored with Roivant.
- Quarterly net loss increased $9.6 million to $41.4 million; nine-month net loss increased $30.3 million to $109.6 million.
- Operating cash use increased $12.3 million to $73.2 million for the nine-month period, while financing proceeds declined from $382.3 million to $200.1 million because the prior-year period included public offerings and warrant redemptions.
- Common shares outstanding increased to 115.1 million at December 31, 2021 from 98.0 million at March 31, 2021, primarily due to the Roivant share issuance.
Guidance, outlook, risks and unusual items
- Management expects existing cash at December 31, 2021 to fund operating expenses and capital expenditures for at least the next 12 months, but states that additional capital will be required to fully implement its business plan. No committed external funding source exists.
- Management planned to initiate a Phase 3 myasthenia gravis study in the first half of calendar 2022, studying weekly 680 mg and 340 mg induction doses. The company also planned studies in warm autoimmune hemolytic anemia and thyroid eye disease and expected two additional indications to be announced by August 2022.
- Clinical dosing for batoclimab had been voluntarily paused since February 2021 after dose-dependent increases in LDL cholesterol and decreases in albumin were observed. The company reported no major adverse cardiovascular events to date, but long-term benefit-risk, dosing, monitoring and risk-mitigation requirements remain uncertain.
- In December 2021, the company announced alignment with the FDA’s Division of Neurology 1 to proceed in myasthenia gravis. This alignment does not constitute marketing approval and future development remains subject to clinical and regulatory results.
- The Samsung manufacturing agreement creates an estimated minimum purchase commitment of approximately $36.0 million, including $17.7 million expected in fiscal 2023 and $18.3 million in fiscal 2026. The agreement also includes potential termination-related payments.
- The HanAll license includes up to $442.5 million of future development, regulatory and sales milestones, reimbursement of up to $20.0 million of specified research and development costs, and tiered royalties generally ranging from the mid-single digits to mid-teens on net sales.
- A putative securities class action filed in February 2021 alleges misleading statements regarding batoclimab’s safety. An amended complaint was filed on February 1, 2022; the company has not accrued a liability because potential losses cannot reasonably be estimated and an unfavorable outcome is not currently determined to be probable.
- COVID-19 slowed prior clinical enrollment but had not caused material financial or manufacturing impacts as of the filing. Future effects on enrollment, supply chains, operations and capital markets remain uncertain.
- Roivant beneficially owned approximately 63.1% of voting power as of February 1, 2022, giving it significant control over elections, equity issuances and other stockholder matters.
Important facts for investors to verify
- Whether the planned Phase 3 myasthenia gravis trial began on schedule and whether its final design, dosing, enrollment and endpoints were accepted by regulators.
- Updated safety data for LDL, total cholesterol and albumin changes, including the effectiveness of proposed monitoring and risk-mitigation measures.
- Cash-burn rate, expected development runway and the timing and terms of any future equity, debt or collaboration financing.
- Progress, costs and remaining obligations under the Samsung manufacturing agreement and the HanAll license, including any triggered milestones.
- Status, estimated exposure and insurance coverage for the securities class action.
- Whether the company can advance indications beyond myasthenia gravis while managing clinical, manufacturing, regulatory and competitive risks.